Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
How to Invest in Biotech Stocks in a Bear Market
06:25am, Wednesday, 13'th Oct 2021
Hint: it doesn't really matter what kind of market it is.
What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"
10:11am, Tuesday, 12'th Oct 2021
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price
Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?
08:49am, Friday, 08'th Oct 2021
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Catalyst Pharmaceuticals Stock Reaches Resistance Level, Looks Ready To Break Out
02:50pm, Wednesday, 06'th Oct 2021
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares are trading higher Wednesday although there looks to be no company-evident news to explain the jump in price. The stock is trading on above-average v
Why Are Catalyst Pharma Shares Trading Higher On Thursday?
03:21pm, Thursday, 30'th Sep 2021
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a favorable decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the FDA approval o
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
12:08pm, Thursday, 30'th Sep 2021
CORAL GABLES, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
A Trio of Stock Picks With Growth Potential
12:43pm, Monday, 20'th Sep 2021
Selecting U.S.-listed equities that have the characteristics listed below represents a solid starting point when in search of potential value opportunities, in my opinion:
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
08:03am, Friday, 17'th Sep 2021
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
08:03am, Friday, 10'th Sep 2021
CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Why Is Catalyst (CPRX) Down 12.6% Since Last Earnings Report?
01:16pm, Wednesday, 08'th Sep 2021
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
08:03am, Monday, 16'th Aug 2021
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
02:04pm, Wednesday, 11'th Aug 2021
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
05:03pm, Tuesday, 10'th Aug 2021
Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call Transcript
03:02pm, Tuesday, 10'th Aug 2021
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call Transcript
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
07:59pm, Monday, 09'th Aug 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 77.78% and 16.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
